Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

Affiliations

• ¹ Cancer Research UK Centre for Drug Development, London, UK. sarah.halford@cancer.org.uk.
• ² Cancer Research UK Centre for Drug Development, London, UK.
• ³ Latus Therapeutics, London, UK.
• ⁴ University of Oxford, Oxford, UK.
• ⁵ Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
• ⁶ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
• ⁷ The University of Edinburgh, Edinburgh, UK.